J. Goldman & CO LP Nektar Therapeutics Transaction History

J. Goldman & CO LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $3.72 Million - $8.4 Million	-80,451 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $596,328 - $1.13 Million	10,389 Added 14.83%	80,451 $8.55 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $3.98 Million - $10.5 Million	-173,038 Reduced 71.18%	70,062 $4.18 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $4.32 Million - $5.83 Million	243,100	243,100 $5.83 Million

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.